Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.43 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7113144 | 0.89 | KMT2A (0.75) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL12914158 | 0.88 | KMT2A (0.58) | KMT2AEPHX2CASP3TLR2FABP5 | |
| SCHEMBL13878698 | 0.85 | KMT2A (0.65) | KMT2AEPHX2CASP3ALDH1A1FABP5 | |
| SCHEMBL13613350 | 0.84 | KMT2A (0.72) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL7103716 | 0.84 | KMT2A (0.68) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL5557575 | 0.82 | KMT2A (0.73) | KMT2AEPHX2CASP3TLR2FABP5 | |
| SCHEMBL19929051 | 0.82 | KMT2A (0.65) | KMT2AEPHX2CASP3TLR2FABP5 | |
| SCHEMBL3699996 | 0.82 | KMT2A (0.64) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL402111 | 0.81 | KMT2A (0.68) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL3757636 | 0.81 | KMT2A (0.72) | KMT2AEPHX2CASP3FABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | claimed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | claimed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| EP-1660507-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-05-31 | — | — | EP | claimed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | claimed |
| WO-2005021558-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| EP-1660507-B2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | MILLENNIUM PHARM INC (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9233115-B2 | Proteasome inhibitors and methods of using the same | MILLENNIUM PHARMACEUTICALS INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | CEPHALON, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8546608-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120041196-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-8058262-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7576206-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | KMT2A 2266/4885EPHX2 3288/4885CASP3 143/4885 |
| US-20120041196-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | KMT2A 2266/4885EPHX2 3288/4885CASP3 143/4885 |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | KMT2A 2266/4885EPHX2 3288/4885CASP3 143/4885 |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | PSMB11, PSMB5, PSMB6 | KMT2A 2266/4885EPHX2 3288/4885CASP3 143/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | KMT2A 2266/4885EPHX2 3288/4885CASP3 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.